StockData
Arrowhead Pharmaceuticals, Inc. logo

Arrowhead Pharmaceuticals, Inc. (ARWR) stock

ARWRNasdaqPharmaceutical PreparationsFiscal year ends September 30
Financials through Q3 FY2026, quarter ended Jun 30, 2026Last filing: 10-K on Nov 12, 2026Score 5/3035% above fair value
$42.99−1.22 (-2.76%)

Close on Nov 17, 2026Market cap $6.07BP/E –Yield –

Arrowhead Pharmaceuticals total assets

Total assets on the balance sheet at the end of each period.

Arrowhead Pharmaceuticals's total assets was $2.11B at Jun 30, 2026. For fiscal 2025 it was $1.39B, up 21.5% from the year before. Over ten years it grew 26.5% a year on average. The highest annual figure on record is $1.39B in fiscal 2025.

Annual total assets

PeriodPeriod endValueChange
FY2025Sep 30, 2025$1.39B+21.5%
FY2024Sep 30, 2024$1.14B+48.9%
FY2023Sep 30, 2023$765.55M+10.6%
FY2022Sep 30, 2022$691.94M-2.6%
FY2021Sep 30, 2021$710.15M+35.9%
FY2020Sep 30, 2020$522.50M+49.4%
FY2019Sep 30, 2019$349.85M+213.5%
FY2018Sep 30, 2018$111.61M+7.3%
FY2017Sep 30, 2017$104.02M-18.8%
FY2016Sep 30, 2016$128.18M-3.1%
FY2015Sep 30, 2015$132.27M-27.7%
FY2014Sep 30, 2014$182.82M+389.7%
FY2013Sep 30, 2013$37.33M+125.9%
FY2012Sep 30, 2012$16.53M+4.0%
FY2011Sep 30, 2011$15.89M+28.6%
FY2010Sep 30, 2010$12.35M–

Quarterly total assets

Change is against the same quarter a year earlier.

Periods
PeriodPeriod endValueChange
Q3 FY2026CQ2 2026Jun 30, 2026$2.11B+53.0%
Q2 FY2026CQ1 2026Mar 31, 2026$2.27B+44.2%
Q1 FY2026CQ4 2025Dec 31, 2025$1.60B+58.3%
Q4 FY2025CQ3 2025Sep 30, 2025$1.39B+21.5%
Q3 FY2025CQ2 2025Jun 30, 2025$1.38B+56.2%
Q2 FY2025CQ1 2025Mar 31, 2025$1.57B+64.7%
Q1 FY2025CQ4 2024Dec 31, 2024$1.01B+61.9%
Q4 FY2024CQ3 2024Sep 30, 2024$1.14B+48.9%
Q3 FY2024CQ2 2024Jun 30, 2024$883.76M+11.0%
Q2 FY2024CQ1 2024Mar 31, 2024$955.15M+7.2%
Q1 FY2024CQ4 2023Dec 31, 2023$626.29M-29.7%
Q4 FY2023CQ3 2023Sep 30, 2023$765.55M+10.6%
Q3 FY2023CQ2 2023Jun 30, 2023$795.86M+5.9%
Q2 FY2023CQ1 2023Mar 31, 2023$891.31M+26.7%
Q1 FY2023CQ4 2022Dec 31, 2022$891.49M+39.6%
Q4 FY2022CQ3 2022Sep 30, 2022$691.94M-2.6%
Q3 FY2022CQ2 2022Jun 30, 2022$751.78M+2.3%
Q2 FY2022CQ1 2022Mar 31, 2022$703.58M-7.0%
Q1 FY2022CQ4 2021Dec 31, 2021$638.54M+27.9%
Q4 FY2021CQ3 2021Sep 30, 2021$710.15M+35.9%
Q3 FY2021CQ2 2021Jun 30, 2021$734.93M+32.2%
Q2 FY2021CQ1 2021Mar 31, 2021$756.80M+34.9%
Q1 FY2021CQ4 2020Dec 31, 2020$499.25M-15.0%
Q4 FY2020CQ3 2020Sep 30, 2020$522.50M+49.4%
Q3 FY2020CQ2 2020Jun 30, 2020$555.73M+65.0%
Q2 FY2020CQ1 2020Mar 31, 2020$561.08M+68.0%
Q1 FY2020CQ4 2019Dec 31, 2019$587.60M+72.3%
Q4 FY2019CQ3 2019Sep 30, 2019$349.85M+213.5%
Q3 FY2019CQ2 2019Jun 30, 2019$336.83M+198.3%
Q2 FY2019CQ1 2019Mar 31, 2019$333.94M+162.9%
Q1 FY2019CQ4 2018Dec 31, 2018$340.95M+286.5%
Q4 FY2018CQ3 2018Sep 30, 2018$111.61M+7.3%
Q3 FY2018CQ2 2018Jun 30, 2018$112.90M-1.9%
Q2 FY2018CQ1 2018Mar 31, 2018$127.00M+0.1%
Q1 FY2018CQ4 2017Dec 31, 2017$88.22M-38.8%
Q4 FY2017CQ3 2017Sep 30, 2017$104.02M-18.8%
Q3 FY2017CQ2 2017Jun 30, 2017$115.08M–
Q2 FY2017CQ1 2017Mar 31, 2017$126.87M–
Q1 FY2017CQ4 2016Dec 31, 2016$144.26M–
Q4 FY2016CQ3 2016Sep 30, 2016$128.18M–

More Arrowhead Pharmaceuticals figures

See a number that looks wrong?